Pyrrolidine

Pyrrolidine

SCHEMBL4843645

C1CCNC1.COc1ccc(-c2nnc(NC3CCN(Cc4ccc(C(=O)O)cc4)CC3)c3cc(OC)ccc23)cc1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 4/20 0.46
LTA4H P09960 3/20 0.45
HDAC3 O15379 5/20 0.45
HDAC1 Q13547 5/20 0.45
HDAC2 Q92769 5/20 0.45
HDAC10 Q969S8 5/20 0.45
HDAC11 Q96DB2 5/20 0.45
HDAC8 Q9BY41 5/20 0.45
HDAC6 Q9UBN7 5/20 0.45
HDAC4 P56524 4/20 0.45
HDAC7 Q8WUI4 4/20 0.45
EHMT2 Q96KQ7 4/20 0.45
HDAC9 Q9UKV0 4/20 0.45
HDAC5 Q9UQL6 4/20 0.45
DNMT3A Q9Y6K1 3/20 0.45
SIGMAR1 Q99720 2/20 0.45
EHMT1 Q9H9B1 1/20 0.45
DRD4 P21917 1/20 0.44
MCHR1 Q99705 2/20 0.42
DNMT1 P26358 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4839200 0.94 ACHE (0.51) ACHELTA4HHDAC3HDAC1HDAC2
Pyrrolidine SCHEMBL5194052 0.88 JAK2 (0.39) ACHELTA4HHDAC3HDAC1HDAC2
SCHEMBL4843086 0.88 ACHE (0.51) ACHEHDAC3HDAC1HDAC2HDAC10
SCHEMBL4843614 0.88 ACHE (0.51) ACHEHDAC3HDAC1HDAC2HDAC10
Hydrochloric Acid SCHEMBL4843163 0.87 ACHE (0.50) ACHEHDAC3HDAC1HDAC2HDAC10
SCHEMBL5196850 0.87 ACHE (0.58) ACHEHDAC3HDAC1HDAC2HDAC10
Hydrochloric Acid SCHEMBL4843091 0.86 ACHE (0.49) ACHEHDAC3HDAC1HDAC2HDAC10
SCHEMBL5193700 0.86 ACHE (0.56) ACHEHDAC3HDAC1HDAC2HDAC10
Hydrochloric Acid SCHEMBL4841854 0.86 ACHE (0.57) ACHEHDAC3HDAC1HDAC2HDAC10
SCHEMBL5195812 0.86 ALDH1A1 (0.54) ACHEHDAC3HDAC1HDAC2HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423030-B2 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof SANOFI-AVENTIS (FR) 2008-09-09 US disclosed
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-05-03 US disclosed
EP-1737840-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-01-03 EP disclosed
WO-2005103033-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF CYP11B2, CYP11B1, GOT2 ACHE 1785/4885LTA4H 2621/4885HDAC3 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.